Dermatite Atopique
Articles
Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results
Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.
Underneath the Skin: Hidden Challenges of Uncontrolled AD and PN
What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?
Advancing Treatment for Uncontrolled AD and PN: New Approaches
As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives8.
Découvrez le mode d’action unique du dupilumab
Dupixent est le premier traitement à moduler spécifiquement les mécanismes immunitaires clés de la dermatite atopique en inhibant les signaux IL-4 et IL-13, principaux facteurs de l’inflammation de type 2.1,2
Exploring the Unique Characteristics of Atopic Dermatitis (AD) and Prurigo Nodularis (PN)
Explore the distinct clinical manifestations of Atopic Dermatitis (AD) and Prurigo Nodularis (PN), their impact on patients' lives, and the common thread of type 2 inflammation. Understand how these chronic skin conditions differ and intersect in this comprehensive overview.
The Long-Term Impact of Early-Onset Atopic Dermatitis
A recent study led by professor Jonathan Silverberg involving over 30,000 participants has highlighted the significant psychosocial burden faced by adults with early-onset atopic dermatitis (AD). Learn more and continue reading.
